Literature DB >> 30443838

Association Between IL7R Promoter Polymorphisms and Multiple Sclerosis in Turkish Population.

Hasan Simsek1, Hikmet Geckin2, Nilay Padir Sensoz3, Edward O List4, Ahmet Arman5,6.   

Abstract

Multiple sclerosis (MS) is a chronic progressive neurodegenerative disease that affects myelin fibers within the central nervous system resulting in neurological impairment. Although the etiology of MS is not fully understood, environmental and genetic factors are thought to play important roles. IL7R gene polymorphisms which are associated with several autoimmune diseases have also been implicated as a genetic factor for MS following genome-wide association studies. To further examine this association, we investigated the association between MS and IL7R gene - 449 (A/G), - 504 (T/C), and - 1085 (G/T) promoter polymorphisms in Turkish population. Three hundred sixty-four MS patients and 191 healthy controls were involved in this study. Three polymorphic regions in the promoter of IL7R were identified and these regions were amplified by appropriate primers. The PCR products were digested by PstI enzyme for - 504 (T/C) SNP and HphI enzyme for - 1085 (G/T) and - 449 (A/G) SNPs and genotyping was done based on digested PCR product sizes. Genotype distributions and allele frequencies of - 449 polymorphism did not show any significant association with MS directly (p = 0.120 and p = 0.490, respectively). But the genotypes of IL7R - 449 GA for AOMS and AA for EOMS were a risk factor in according to age of onset (p = 0.002, OR = 4.021, 95% CI = 1.642-9.845). Furthermore, IL7R - 449 A allele was found to be a risk factor for EOMS (p = 0.011, OR = 1.3, 95% CI = 1.107-1.527). Significant association was seen between IL7R - 504 TC heterozygote genotype and MS (p = 0.02, OR = 1.702, 95% CI = 1.169-2.478). The IL7R - 1085 (G/T) polymorphism did not show association with MS; however, the haplotype of ACG may be susceptibility to MS and RRMS (p = 0.035, OR = 1.349, 95% CI = 1.020-1.785, and p = 0.041, OR = 1.368, 95% CI = 1.012-1.850, respectively) and the haplotypes of ACG, ATT, and GTG demonstrate a protective effect in EOMS (p = 0.008, OR = 0.326, 95% CI = 0.136-0.782, p = 0.012 and p = 0.012, OR = 0.462, 95% CI = 0.249-0.859, respectively). RRMS frequency in the Turkish population was decreased and SPMS frequency was strongly increased based on comparison to results from other populations. Furthermore, male patients had an increased frequency of SPMS significantly (p = 0.033, OR = 1.667, 95% CI = 1.036-2.682). In conclusion, this is the first study to show a significant association between the IL7R promoter polymorphisms and the age of onset of MS.

Entities:  

Keywords:  IL7R; Inflammation; Multiple sclerosis; Polymorphism

Mesh:

Substances:

Year:  2018        PMID: 30443838     DOI: 10.1007/s12031-018-1205-0

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  49 in total

1.  A new statistical method for haplotype reconstruction from population data.

Authors:  M Stephens; N J Smith; P Donnelly
Journal:  Am J Hum Genet       Date:  2001-03-09       Impact factor: 11.025

Review 2.  The prevalence of multiple sclerosis in the world: an update.

Authors:  G Rosati
Journal:  Neurol Sci       Date:  2001-04       Impact factor: 3.307

3.  Cutting edge: depletion of CD4+CD25+ regulatory T cells is necessary, but not sufficient, for induction of organ-specific autoimmune disease.

Authors:  Rebecca S McHugh; Ethan M Shevach
Journal:  J Immunol       Date:  2002-06-15       Impact factor: 5.422

4.  Age at onset in multiple sclerosis.

Authors:  M Liguori; M G Marrosu; M Pugliatti; F Giuliani; F De Robertis; E Cocco; G B Zimatore; P Livrea; M Trojano
Journal:  Neurol Sci       Date:  2000       Impact factor: 3.307

5.  Late-onset multiple sclerosis.

Authors:  M L Polliack; Y Barak; A Achiron
Journal:  J Am Geriatr Soc       Date:  2001-02       Impact factor: 5.562

6.  Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans.

Authors:  Jorge R Oksenberg; Lisa F Barcellos; Bruce A C Cree; Sergio E Baranzini; Teodorica L Bugawan; Omar Khan; Robin R Lincoln; Amy Swerdlin; Emmanuel Mignot; Ling Lin; Douglas Goodin; Henry A Erlich; Silke Schmidt; Glenys Thomson; David E Reich; Margaret A Pericak-Vance; Jonathan L Haines; Stephen L Hauser
Journal:  Am J Hum Genet       Date:  2003-12-10       Impact factor: 11.025

7.  Multiple sclerosis in US veterans of the Vietnam era and later military service: race, sex, and geography.

Authors:  Mitchell T Wallin; William F Page; John F Kurtzke
Journal:  Ann Neurol       Date:  2004-01       Impact factor: 10.422

8.  Identification of 11 novel and common single nucleotide polymorphisms in the interleukin-7 receptor-alpha gene and their associations with multiple sclerosis.

Authors:  Suzy M Teutsch; David R Booth; Bruce H Bennetts; Robert N S Heard; Graeme J Stewart
Journal:  Eur J Hum Genet       Date:  2003-07       Impact factor: 4.246

9.  Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability.

Authors:  J H van Waesberghe; W Kamphorst; C J De Groot; M A van Walderveen; J A Castelijns; R Ravid; G J Lycklama à Nijeholt; P van der Valk; C H Polman; A J Thompson; F Barkhof
Journal:  Ann Neurol       Date:  1999-11       Impact factor: 10.422

10.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

View more
  1 in total

1.  Identifying the pattern of immune related cells and genes in the peripheral blood of ischemic stroke.

Authors:  Zijian Li; Yueran Cui; Juan Feng; Yanxia Guo
Journal:  J Transl Med       Date:  2020-08-03       Impact factor: 5.531

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.